Health Catalyst, Inc.
HCATDrugs in Pipeline
9
Phase 3 Programs
9
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Budesonide
Colitis, Ulcerative
Plecanatide
Chronic Idiopathic Constipation
Rifaximin
Hepatic Encephalopathy
Methylnaltrexone
Post-Operative Ileus (POI)
Crofelemer
HIV Enteropathy
MOA-728
Ileus
N-methylnaltrexone bromide (MOA-728)
Constipation
SC Methylnaltrexone
Advanced Illness Patients With Opioid Induced Constipation
Tramadol HCl ER
Chronic Pain
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Budesonide | Phase 3 | Colitis, Ulcerative | - | - |
Plecanatide | Phase 3 | Chronic Idiopathic Constipation | - | - |
Rifaximin | Phase 3 | Hepatic Encephalopathy | - | - |
Methylnaltrexone | Phase 3 | Post-Operative Ileus (POI) | - | - |
Crofelemer | Phase 3 | HIV Enteropathy | - | - |
MOA-728 | Phase 3 | Ileus | - | - |
N-methylnaltrexone bromide (MOA-728) | Phase 3 | Constipation | - | - |
SC Methylnaltrexone | Phase 3 | Advanced Illness Patients With Opioid Induced Constipation | - | - |
Tramadol HCl ER | Phase 3 | Chronic Pain | - | - |